The company said worldwide revenues rose 2.6% from the prior-year period to $4.706 billion over the 3 months ended December 31, 2023.

1. 01

   The company said worldwide revenues rose 2.6% from the prior-year period to $4.706 billion over the 3 months ended December 31, 2023.

2. 02

   Becton Dickinson said China market dynamics, including volume-based procurement programs (VoBP), had an adverse impact on its results, particularly in the Medical segment, and that these dynamics may continue to weigh on results throughout fiscal 2024.

3. 03

   The company said cash flows from operating activities were $855 million in the first 3 months of fiscal 2024, and that it paid cash dividends to common shareholders of $275 million over the same period.

4. 04

   The company said it held $1.236 billion in cash and equivalents and short-term investments, including restricted cash, as of December 31, 2023, and that there were no borrowings outstanding under its $2.750 billion revolving credit facility.

Key figures

Quarter ended December 31, 2023

Revenue

$4.7B

Operating income

$439M

Net income

$281M

EPS

$0.96

Operating cash flow

$855M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.